Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Metastatic Breast Cancer at ASCO 2023 ...Middle East

ORSERDU (elacestrant) was approved by the FDA in January 2023 for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with ESR1-mutations (ESR1-mut) that are found in up to 40% of tumors In patients whose tumors...

Hence then, the article about menarini group shares new analysis from emerald clinical study of orserdu elacestrant in metastatic breast cancer at asco 2023 was published today ( Friday 26/05/2023 - 02:00 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Metastatic Breast Cancer at ASCO 2023 )

Also on site :

• ‘A little touch of luxury, it goes a long way’: Starbucks CEO sees the turn in the turnaround as human touch sings
• Best-Selling Author’s Novel, Ranked ‘Readers’ Favorite Mystery and Thriller,’ Was Built on a Wild Premise
• Keke Palmer Is Really Excited About Hosting Billboard Women in Music 2026 and Performing New Single’Text Message Unsent’